GlassScriptPhysician profile
Lorne W Murray
NPI 1609857705
$5,844.26
in general payments reported to CMS, 2019-2025
29 companies · $680 in 2025
The $680 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,167 · 2020: $163 · 2021: $486 · 2022: $1,097 · 2023: $1,706 · 2024: $545 · 2025: $680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,931.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,931.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,081.49 | 2019-2025 | Aveir, Eterna, Gallant |
| Boston Scientific Corporation | $1,000.42 | 2019-2023 | Lux-Dx Insertable Cardiac Monitor |
| Abiomed | $654.81 | 2023-2025 | Impella |
| Shockwave Medical, INC | $575.32 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $467.07 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $381.72 | 2019-2022 | |
| Amgen INC. | $351.30 | 2019-2024 | Repatha |
| Organogenesis INC. | $257.62 | 2023 | Puraply |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $215.27 | 2019-2024 | Lifevest |
| Baxter Healthcare | $98.96 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Alexion Pharmaceuticals, INC. | $98.45 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $96.32 | 2022-2024 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals LP | $76.50 | 2019-2024 | Farxiga |
| Sanofi-Aventis U.S. LLC | $55.27 | 2023 | |
| Merck Sharp & Dohme LLC | $54.14 | 2022-2023 | Verquvo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $53.64 | 2025 | Zenpep |
| Pfizer INC. | $48.73 | 2022-2024 | |
| Cardiovascular Systems INC. | $41.67 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $35.06 | 2024-2025 | Eliquis, Camzyos |
| Terumo Medical Corporation | $34.36 | 2022-2024 | Angio-Seal |
| Amarin Pharma, INC. | $31.90 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $23.11 | 2025 | Recorlev |
| Recordati_rare_diseases_inc. | $19.02 | 2024 | Signifor Lar, Isturisa |
| Lexicon Pharmaceuticals, INC. | $18.54 | 2023 | Inpefa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.39 | 2025 | Jardiance |
| Tactile Systems Technology INC | $14.95 | 2023 | Flexitouch Plus, Entre Plus |
| Astellas Pharma US INC | $14.32 | 2020 | |
| Philips North America LLC | $14.09 | 2023 | |
| Esperion Therapeutics, INC. | $13.82 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorne Murray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.